Peripheral PDLIM5 Expression in Bipolar Disorder and the Effect of Olanzapine Administration

Overview

Journal BMC Med Genet

Publisher Biomed Central

Specialty Genetics

Date 2012 Oct 4

PMID 23031404

Citations 4

Authors

Mohd Aizat Zain

Suffee Nusrat Jahan

Gavin P Reynolds

Nor Zuraida Zainal

Sharmilla Kanagasundram

Zahurin Mohamed

Affiliations

Soon will be listed here.

Abstract

Background: One of the genes suggested to play an important role in the pathophysiology of bipolar disorder (BPD) is PDLIM5, which encodes LIM domain protein. Our main objective was to examine the effect of olanzapine treatment on PDLIM5 mRNA expression in the peripheral blood leukocytes of BPD patients.

Methods: We measured the expression of PDLIM5 mRNA from 16 patients with BPD Type I after 0, 4, and 8 weeks of treatment with olanzapine using quantitative real-time PCR. The Young Mania Rating Scale was used to evaluate the severity of manic symptoms in BPD patients. We also compared PDLIM5 mRNA expression in treatment-naïve BPD patients with that in healthy control subjects.

Results: No significant difference was found in PDLIM5 mRNA expression between patients before olanzapine treatment and following 4 and 8 weeks of treatment (p>0.05). Although we observed a significant reduction in the severity of manic symptoms in all BPD patients (p<0.05), the effectiveness of the medication did not significantly correlate with the expression of PDLIM5 mRNA (p>0.05). Interestingly, PDLIM5 mRNA expression differed significantly between treatment-naïve BPD patients and healthy control subjects (p=0.002).

Conclusion: PDLIM5 mRNA expression did not appear to be a reflection of the efficacy of olanzapine in reducing the manic symptoms of BPD. The significant difference in expression of PDLIM5 mRNA in the peripheral blood leukocytes of treatment-naïve BPD patients versus that of healthy control subjects, however, suggests that it may be a good biological marker for BPD.

Citing Articles

A Systematic Review of the Molecular and Cellular Alterations Induced by Cannabis That May Serve as Risk Factors for Bipolar Disorder.

Delgado-Sequera A, Garcia-Mompo C, Gonzalez-Pinto A, Hidalgo-Figueroa M, Berrocoso E Int J Neuropsychopharmacol. 2024; 27(2).

PMID: 38175142 PMC: 10863486. DOI: 10.1093/ijnp/pyae002.

The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review.

Routhieaux M, Keels J, Tillery E Ment Health Clin. 2018; 8(6):294-302.

PMID: 30397571 PMC: 6213894. DOI: 10.9740/mhc.2018.11.294.

Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia.

Mamdani F, Martin M, Lencz T, Rollins B, Robinson D, Moon E Dis Markers. 2013; 35(1):11-21.

PMID: 24167345 PMC: 3774957. DOI: 10.1155/2013/748095.

Experimental evidence for the involvement of PDLIM5 in mood disorders in hetero knockout mice.

Horiuchi Y, Ishikawa M, Kaito N, Iijima Y, Tanabe Y, Ishiguro H PLoS One. 2013; 8(4):e59320.

PMID: 23593136 PMC: 3620230. DOI: 10.1371/journal.pone.0059320.

References

Tohen M, Baker R, Altshuler L, Zarate C, Suppes T, Ketter T . Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002; 159(6):1011-7. DOI: 10.1176/appi.ajp.159.6.1011. View

Iga J, Ueno S, Yamauchi K, Numata S, Motoki I, Tayoshi S . Gene expression and association analysis of LIM (PDLIM5) in major depression. Neurosci Lett. 2006; 400(3):203-7. DOI: 10.1016/j.neulet.2006.02.044. View

van Loo K, Martens G . Genetic and environmental factors in complex neurodevelopmental disorders. Curr Genomics. 2009; 8(7):429-44. PMC: 2647153. DOI: 10.2174/138920207783591717. View

Horiuchi Y, Arai M, Niizato K, Iritani S, Noguchi E, Ohtsuki T . A polymorphism in the PDLIM5 gene associated with gene expression and schizophrenia. Biol Psychiatry. 2005; 59(5):434-9. DOI: 10.1016/j.biopsych.2005.07.041. View

Squassina A, Congiu D, Manconi F, Manchia M, Chillotti C, Lampus S . The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacol Res. 2008; 57(5):369-73. DOI: 10.1016/j.phrs.2008.03.011. View

Kato T . Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci. 2007; 61(1):3-19. DOI: 10.1111/j.1440-1819.2007.01604.x. View

Shi J, Badner J, Liu C . PDLIM5 and susceptibility to bipolar disorder: a family-based association study and meta-analysis. Psychiatr Genet. 2008; 18(3):116-21. PMC: 2572255. DOI: 10.1097/YPG.0b013e3282fa184b. View

Shi Y, He L . SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005; 15(2):97-8. DOI: 10.1038/sj.cr.7290272. View

Kuroda S, Tokunaga C, Kiyohara Y, Higuchi O, Konishi H, Mizuno K . Protein-protein interaction of zinc finger LIM domains with protein kinase C. J Biol Chem. 1996; 271(49):31029-32. DOI: 10.1074/jbc.271.49.31029. View

10.

Zhao T, Liu Y, Wang P, Li S, Zhou D, Zhang D . Positive association between the PDLIM5 gene and bipolar disorder in the Chinese Han population. J Psychiatry Neurosci. 2009; 34(3):199-204. PMC: 2674973. View

11.

Mehta D, Menke A, Binder E . Gene expression studies in major depression. Curr Psychiatry Rep. 2010; 12(2):135-44. PMC: 2847693. DOI: 10.1007/s11920-010-0100-3. View

12.

Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T . Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry. 2004; 9(4):406-16. DOI: 10.1038/sj.mp.4001437. View

13.

Kato T, Iwayama Y, Kakiuchi C, Iwamoto K, Yamada K, Minabe Y . Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia. Mol Psychiatry. 2005; 10(11):1045-55. DOI: 10.1038/sj.mp.4001719. View

14.

Singh R, Shi J, Zemaitaitis B, Muma N . Olanzapine increases RGS7 protein expression via stimulation of the Janus tyrosine kinase-signal transducer and activator of transcription signaling cascade. J Pharmacol Exp Ther. 2007; 322(1):133-40. DOI: 10.1124/jpet.107.120386. View

15.

Iwamoto K, Bundo M, Washizuka S, Kakiuchi C, Kato T . Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. J Hum Genet. 2004; 49(5):227-31. DOI: 10.1007/s10038-004-0136-5. View

16.

Tohen M, Chengappa K, Suppes T, Zarate Jr C, Calabrese J, Bowden C . Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59(1):62-9. DOI: 10.1001/archpsyc.59.1.62. View

17.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

18.

Numata S, Ueno S, Iga J, Yamauchi K, Hongwei S, Hashimoto R . Gene expression in the peripheral leukocytes and association analysis of PDLIM5 gene in schizophrenia. Neurosci Lett. 2007; 415(1):28-33. DOI: 10.1016/j.neulet.2007.01.018. View

19.

Vacheron-Trystram M, Braitman A, Cheref S, Auffray L . [Antipsychotics in bipolar disorders]. Encephale. 2005; 30(5):417-24. DOI: 10.1016/s0013-7006(04)95456-5. View

20.

Hahn C, Friedman E . Abnormalities in protein kinase C signaling and the pathophysiology of bipolar disorder. Bipolar Disord. 2001; 1(2):81-6. DOI: 10.1034/j.1399-5618.1999.010204.x. View